Linezolid - A synthetic oxazolidinone antimicrobial for treatment of serious gram-positive infections (vol 35, pg 483, 2000)

被引：0
|
作者：
CupoAbbott, J
机构：
来源：
FORMULARY | 2000年 / 35卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：736 / 736
页数：1
相关论文
共 50 条
  • [1] Linezolid - A synthetic oxazolidinone antimicrobial for treatment of serious gram-positive infections
    Cupo-Abbott, J
    Louie, SG
    Rho, JP
    FORMULARY, 2000, 35 (06) : 483 - +
  • [2] Linezolid: a novel oxazolidinone antimicrobial for the treatment of serious Gram-positive infections - Preface
    Reeves, D
    Wilson, P
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 : 1 - 1
  • [3] Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections
    Chien, JW
    Kucia, ML
    Salata, RA
    CLINICAL INFECTIOUS DISEASES, 2000, 30 (01) : 146 - 151
  • [4] Linezolid - A review of its use in the management of serious Gram-positive infections
    Perry, CM
    Jarvis, B
    DRUGS, 2001, 61 (04) : 525 - 551
  • [5] Linezolid - A pharmacoeconomic review of its use in serious gram-positive infections
    Plosker, GL
    Figgitt, DP
    PHARMACOECONOMICS, 2005, 23 (09) : 945 - 964
  • [6] Emerging therapies for serious gram-positive bacterial infections: A focus on linezolid
    Plouffe, JF
    CLINICAL INFECTIOUS DISEASES, 2000, 31 : S144 - S149
  • [7] Linezolid in the treatment of Gram-positive prosthetic joint infections
    Bassetti, M
    Vitale, F
    Melica, G
    Righi, E
    Di Biagio, A
    Molfetta, L
    Pipino, F
    Cruciani, M
    Bassetti, D
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (03) : 387 - 390
  • [8] Telavancin: An antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections
    Leonard, Steven N.
    Rybak, Michael J.
    PHARMACOTHERAPY, 2008, 28 (04): : 458 - 468
  • [9] Benefit-Risk Assessment of Linezolid for Serious Gram-Positive Bacterial Infections
    Matthew E. Falagas
    Konstantinos Z. Vardakas
    Drug Safety, 2008, 31 : 753 - 768
  • [10] Benefit-risk assessment of linezolid for serious Gram-positive bacterial infections
    Falagas, Matthew E.
    Vardakas, Konstantinos Z.
    DRUG SAFETY, 2008, 31 (09) : 753 - 768
12345